Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Endocrinology | Family Medicine | Internal Medicine | Neurology | Nursing | Pharmacy | Journal

Back to Journal Articles

Statin Benefits Outweigh Risk of Developing Diabetes

Last Updated: August 10, 2012.

 

Diabetes risk only increased in those with one or more major risk factors

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Statins increase the risk of developing diabetes, but only in individuals already at risk of the disease, and the benefits of statins in the prevention of cardiovascular disease and death outweigh the risks, according to a study published in the Aug. 11 issue of The Lancet.

FRIDAY, Aug. 10 (HealthDay News) -- Statins increase the risk of developing diabetes, but only in individuals already at risk of the disease, and the benefits of statins in the prevention of cardiovascular disease and death outweigh the risks, according to a study published in the Aug. 11 issue of The Lancet.

To determine the vascular benefit and diabetes hazard profile of statins, Paul M. Ridker, M.D., from Brigham and Women's Hospital in Boston, and colleagues analyzed results from a clinical trial involving 17,603 individuals free of vascular disease or diabetes who had been randomized to treatment with 20 mg rosuvastatin or placebo and followed for up to five years.

The researchers found that only individuals with at least one major risk factor for diabetes had an increased risk of diabetes (28 percent greater). However, these individuals also had a significantly reduced risk of vascular disease and death, although the risk reduction was smaller than for those without major risk factors for diabetes. For those with diabetes risk factors, a total of 134 vascular events or deaths were avoided for every 54 new cases of diabetes diagnosed. For those without diabetes risk factors, a total of 86 vascular events or deaths were avoided with no new cases of diabetes diagnosed.

"For our patients, we hope these data ease concern about risks associated with statin therapy when these drugs are appropriately prescribed for cardiovascular risk reduction as an adjunct to dietary discretion, increased exercise, and smoking cessation," Ridker and colleagues conclude.

Several authors disclosed financial relationships with drug companies, including AstraZeneca, which funded the study.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Good Stability With Artificial Disc Plus Cage Fusion Next: Prognostic Factors Identified in Mucoepidermoid Carcinoma

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.